首页 正文

Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence

{{output}}
Since the COVID-19 pandemic, patients with immune-mediated inflammatory diseases (IMID) are recommended to receive SARS-CoV-2 vaccinations to reduce complications following COVID-19 infection. We conducted a case-control study and case analysis to investigate ... ...